INKTHealthcare · BiotechnologyThe 2 Wall Street analysts covering MiNK Therapeutics, Inc. hold a median 12-month price target of $39 — +219.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores MiNK Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (24): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INKT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +219.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $35 |
| 1 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 15 July 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 14 July 2025 | William Blair | Downgrade | Market Perform | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2024 | Baird | Maintains | Outperform | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Mar 2023 | Evercore ISI Group | Maintains | Outperform | — |
| 22 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Aug 2022 | HC Wainwright & Co. | Initiates | Buy | — |
| 24 Jan 2022 | B. Riley Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INKT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 97% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 95% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MiNK Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MiNK Therapeutics published the transcript of its Q2 2026 earnings call via Seeking Alpha. The document covers the company's financial results and management commentary for the quarter.
Why it matters — An INKT watcher would look to this transcript for the company's latest financial results and management's remarks on its clinical programs and outlook.
MiNK Therapeutics announced during its Q2 2026 earnings call that it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome (ARDS).
Why it matters — A MiNK Therapeutics watcher would care because advancing agenT-797 into a randomized Phase II trial marks a key clinical milestone for the company's lead pipeline candidate.
MiNK Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797. The company also reported observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.
Why it matters — The update provides INKT watchers with the company's latest financial position and new clinical data on its lead iNKT cell therapy candidate, agenT-797.
MiNK Therapeutics announced it will report its second quarter 2026 financial results before the market opens on Thursday, August 13, 2026, and will host a conference call and webcast at 8:30 AM ET that morning. The call will review financial results and provide a corporate update focused on the clinical advancement of its off-the-shelf allogeneic iNKT cell therapy agenT-797 in acute lung injury.
Why it matters — This item flags an upcoming investor update that will include clinical progress on agenT-797 in acute lung injury, a key program for MiNK.
The 2 Wall Street analysts covering MiNK Therapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $35 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering MiNK Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MiNK Therapeutics, Inc. 57 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, MiNK Therapeutics, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +219.9% from the last close, and Ticker Nerd's factor model ranks MiNK Therapeutics, Inc. 57 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MiNK Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $43 over the next 12 months.
MiNK Therapeutics, Inc. returned -18.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript". MiNK Therapeutics published the transcript of its Q2 2026 earnings call via Seeking Alpha. The document covers the company's financial results and management commentary for the quarter.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company focuses on off-the-shelf, cryopreserved cell products designed to reconstitute and rebalance the immune system without the need for patient-specific manufacturing. Its lead candidate, agenT-797, is an allogeneic native iNKT cell therapy being evaluated in clinical trials for solid tumors, graft-versus-host disease, and severe pulmonary inflammation, including acute respiratory distress–type conditions. Alongside this flagship program, MiNK Therapeutics is advancing engineered iNKT candidates such as MiNK-215, targeting tumor stroma via FAP-CAR-iNKT, and MiNK-413, a CAR-iNKT therapy directed at B cell maturation antigen for immune and inflammatory settings. By bridging innate and adaptive immunity through its proprietary iNKT platform and scalable manufacturing processes, MiNK Therapeutics plays a specialized role in the biotechnology sector, aiming to provide “living drug” immunotherapies to address areas of high unmet medical need. Founded in 2017, the company is headquartered in New York, United States.
CEO Dr. Jennifer S. Buell Ph.D. · 15 employees · United States · https://minktherapeutics.com